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Abstract
Background: In the last years, several susceptibility genes for psychiatric disorders have been
identified, among others G72 (also named D-amino acid oxidase activator, DAOA). Typically, the
high-risk variant of a vulnerability gene is associated with decreased cognitive functions already in
healthy individuals. In a recent study however, a positive effect of the high-risk variant of G72 on
verbal working memory was reported. In the present study, we therefore examined the
relationship between G72 genotype status and a broad range of cognitive functions in 423 healthy
individuals.
Methods: The G72 carrier status was assessed by the two single nucleotide polymorphisms
(SNPs) M23 and M24. Subjects were divided into three risk groups (low, intermediate and high
risk).
Results: G72 status influenced a number of cognitive functions, such as verbal working memory,
attention, and, at a trend level, spatial working memory and executive functions. Interestingly, the
high-risk allele carriers scored better than one or even both other groups.
Conclusion: Our data show that the putative high-risk haplotype (i.e. homozygote C/C-allele
carriers in SNP M23 and homozygote T/T-allele carriers in SNP M24) is in healthy individuals not
necessarily associated with worse performance in cognitive functions, but even with better
performance in some domains. Further work is required to identify the mechanisms of G72 on
brain functions.
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Background
Cognitive functions are impaired in schizophrenia [1,2]
and, to a lesser extent, also in bipolar disorder [3,4] and
major depression [5]. Among the different cognitive
domains, verbal memory, verbal fluency and attention are
typically most affected [2,3,5,6]. Especially in schizophre-
nia, these impairments are already present in adolescence,
long before the onset of psychotic symptoms [4,6], in the
prodromal state [7] and can also be found in relatives of
patients [8,9], suggesting a genetic influence.
In the last years, several susceptibility genes for psychiatric
disorders have been identified (for reviews, see [10-13].
Among these, G72 (recently named D-amino acid oxidase
activator, DAOA) is one of the most frequently replicated
vulnerability genes [14]. It shows a genetic overlap across
the major psychoses, such as bipolar disorder, major
depression and schizophrenia [15-21], questioning the
long-held view of a strict nosological separation of psychi-
atric disorders [16,17].
To reveal potential in vivo functions of risk genes several
studies have assessed genotype effects in healthy individ-
uals. For several risk alleles, an association with subtle
impairments in cognitive functions (e.g., [22]) or disad-
vantageous personality traits (e.g., [21,23,24]) have been
found, although this does depend on the gene and the
respective tagging marker.
In a recent study, we investigated the effect of G72 geno-
type on working memory using both neuropsychological
tests and functional neuroimaging. Unexpectedly, the
putative high-risk haplotype (i.e. homozygote C/C-allele
carriers in the single nucleotide polymorphism (SNP)
M23 and homozygote T/T-allele carriers in SNP M24) was
associated with significant better  performance in verbal
working memory. These behavioural differences were
accompanied by a stronger deactivation in the right para-
hippocampus during a working memory 2-back task [25].
Thus, the high risk variant of G72 has a beneficial influ-
ence on verbal working memory in healthy subjects,
although it is known to increase the risk for schizophrenia
and affective disorders, diseases that are associated with
impairments in this domain [2,3,5,6].
In the present study we further investigated how genetic
alterations in G72 influence cognitive functions in healthy
individuals. We examined whether the positive influence
of the high risk G72 variant is restricted to verbal working
memory or whether this genotype also beneficially influ-
ences other cognitive domains.
Methods
Subjects
The subjects were recruited through postings at the Uni-
versity of Aachen, advertisements in local newspapers and
an e-mail sent to all students of the University of Aachen.
423 subjects (214 men, 209 women) were included in the
present study. Inclusion criteria were age (18-55 years),
right-handedness (as assessed by the Edinburgh Laterality
Scale, [26]), no psychiatric disorders according to ICD-10
and Western- or Middle European descent. The subjects'
characteristics are given in Table 1a.
After a complete description of the procedure subjects
provided written informed consent to participate in the
study. The protocol was approved by the local ethics com-
mittee according to the declaration of Helsinki. After par-
Table 1: G72 risk status
G72 risk status low intermediate high F p
a: Subjects' characteristics
number of subjects 88 231 104
Sex ratio (men/women) 43/45 115/116 56/48 χ2 = 0.606 .739
Age (years) 25.0 (6.7) 24.9 (6.3) 23.8 (3.7) 1.387 .251
Education (years) 15.5 (2.6) 15.5 (2.8) 15.5 (2.2) .005 .995
b: Cognitive variables
Spatial span 19.09 (2.88) 18.82 (3.12) 19.62 (2.60) 2.585 .077
Letter-number-span test 16.36 (2.51) 16.28 (2.55) 17.32 (2.26) 6.636 .001 *
Trail Making Test 58.29 (15.01) 62.85 (19.67) 57.31 (15.42) 4.357 .013
Semantic verbal fluency 30.75 (8.88) 30.91 (9.21) 32.81 (9.63) 1.734 .178
Lexical verbal fluency 17.38 (4.25) 16.54 (4.47) 16.89 (5.08) 1.096 .335
d2-test 201.3 (35.7) 188.0 (33.5) 198.8 (33.8) 6.545 .002 *
Subjects are divided into three groups (low, intermediate and high risk) according to their G72 status (based on two SNPs, M23 and M24). (a) 
Subjects' characteristics: sex, age and education. There were no significant group differences in sex ratio, age or education (p > .1). (b) Cognitive 
results of a neuropsychological test battery testing working memory, executive functions, verbal fluency and attention. Due to Bonferroni 
corrections for multiple testing, a significance threshold of p = 0.008 was set as significance criterion. Standard deviations are given in parentheses. 
Significant results are marked with '*'.BMC Psychiatry 2009, 9:60 http://www.biomedcentral.com/1471-244X/9/60
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ticipants provided consent, the cognitive tests were
administered and blood was taken from a vein of each
subject's arm.
Genetic Analysis
Subjects were genotyped as part of a sample described in
Rietschel et al. [21] for two G72 SNPs (M23 = rs3918342
[C/T] and M24 = rs1421292 [T/A]) using the MassARRAY®
system (Sequenom Inc., San Diego, Ca). For quality com-
parison purposes, we genotyped a subset of the sample in
duplicate in order to estimate the replicate error rate. Two
out of 96 DNA samples were randomly chosen for this
purpose. For the SNPs genotyped, all genotypes between
duplicates were consistent (0% replicate error rate). We
also always include routinely positive and negative con-
trols in our genotyping experiments. By a standard 1 df
chi-square test, there were no significant deviations from
Hardy-Weinberg equilibrium for the genotype distribu-
tions of the studied sample.
The association between G72 genotype status and psychi-
atric disorders was obtained for different SNPs [14,27-29].
We chose the markers M23 and M24, because the M23-
M24 haplotypes C-T and T-A have recently been associ-
ated with schizophrenia, bipolar disorder, and major
depression [21]. Depending on the M23 and M24 mark-
ers, the subjects were divided in three groups: low risk,
intermediate risk and high risk. Subjects who had a
homozygote T-allele on M23 and a homozygote A-allele
on M24 were classified as "low risk". Subjects who had a
homozygote C-allele on M23 and a homozygote T-allele
on M24 were classified as "high risk". All other subjects
belonged to the "intermediate risk" group.
In a post-hoc analysis, we additionally analysed all data
separately for group classifications depending solely on
the M23 and M24 status, respectively. The principal
results did not change (see appendix and tables 2 and 3).
This is not surprising, since both markers are highly corre-
lated (r = 0.94).
Neuropsychological test battery
We assessed working memory, executive functions, verbal
fluency and attention. Working memory was measured
with the spatial span of the Wechsler Memory Scale (spa-
tial working memory, [30]) and with the letter-number-
span test (verbal working memory, [31]). Executive func-
tions were assessed with the Trail Making Test (TMT-B,
[32]). Verbal fluency was measured with semantic and lex-
ical word generation [33]. Attention was assessed with the
d2-test [34].
Behavioural data were analyzed using a univariate
ANOVA design with G72 status (low, intermediate and
high risk) as factor between subjects and outcome of the
cognitive assessments as dependent variables. Bonferroni
correction was applied to correct for multiple statistical
testing (six tests, p = 0.008). In a post-hoc analysis, we
additionally included age as covariate (since age is known
to be significantly correlated with most of the dependent
variables). The principal results however did not change.
Results
The ANOVA showed a significant (p < 0.008) main effect
of G72 status on verbal working memory (p = 0.001, the
high risk group performed better than both other groups)
and attention (p = 0.002, the intermediate risk group per-
formed worse than both other groups). Furthermore,
there was a trend (p < 0.1) effect of G72 status on spatial
working memory (p = 0.077, the high risk group per-
formed better than both other groups) and executive func-
tion (p = 0.013, the intermediate risk group performed
worse than both other groups) (Table 1b).
Table 2: Risk status calculated by M23
G72 risk status (M23) low intermediate high F p
a: Subjects' characteristics
number of subjects 95 221 107
Sex ratio (men/women) 49/46 108/113 57/50 0.607 .738
Age (years) 24.9 (6.5) 25.0 (6.4) 23.8 (3.6) 1.592 .205
Education (years) 15.6 (2.6) 15.5 (2.8) 15.5 (2.2) 0.068 .935
b: Cognitive variables
Spatial span 19.19 (2.85) 18.80 (3.14) 19.53 (2.65) 2.304 .101
Letter-number-span test 16.41 (2.49) 16.25 (2.58) 17.28 (2.25) 6.496 .002
Trail Making Test 58.41 (14.62) 62.81 (19.95) 57.73 (15.39) 3.804 0.23
Semantic verbal fluency 30.76 (8.72) 31.00 (9.31) 32.57 (9.61) 1.277 .280
Lexical verbal fluency 17.25 (4.27) 16.57 (4.48) 16.87 (5.05) 0.753 .472
d2-test 200.9 (35.0) 187.6 (33.4) 198.8 (34.3) 6.832 .001BMC Psychiatry 2009, 9:60 http://www.biomedcentral.com/1471-244X/9/60
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Discussion
In the present study we investigated the effect of G72 gen-
otype on cognitive functions in a large sample of healthy
individuals. Our results show that G72 status influences
the performance in a number of cognitive domains (sig-
nificant differences in verbal working memory and atten-
tion, differences on a trend level in spatial working
memory and executive functions). Most importantly, the
high-risk allele carriers scored significantly better than one
or even both other low-risk groups. Thus, healthy individ-
uals with a G72 haplotype that is known to increase the
risk for the major psychoses perform better in some cog-
nitive domains than subjects with a low risk status,
although these cognitive domains are negatively affected
by the psychiatric disorders that are associated with this
allele variant.
Only few studies assessed so far the effect of genetic varia-
tion in G72 on cognitive functions. Goldberg et al. inves-
tigated the relationship between several SNPs in the G72
region and select cognitive measures in attention, working
memory, and episodic memory in a cohort of over 600
subjects, including patients with schizophrenia, their
unaffected siblings, and healthy controls. The authors
showed for the markers M23 and M24 a significant geno-
type by diagnosis interaction with a number of cognitive
measures (working memory, attention, verbal learning).
The low risk homozygote A/A genotype group scored bet-
ter than the high risk T/T homozygote group, most nota-
bly in the schizophrenia group [35]. Although the authors
also report a main effect of genotype at least for marker
M24, this effect seems to be mainly driven by the patient
sample. Opgen-Rhein and colleagues investigated the
influence of G72 variation on cognitive performance in a
large sample of both patients schizophrenia (n = 178) and
healthy controls (n = 144) [36]. They showed that a cer-
tain G72  haplotype located upstream of the presumed
gene borders of G72 has an impact on semantic fluency.
Interestingly, carriers of the risk haplotype showed better
semantic fluency than non-carriers, both in the patients
and the control population. Donohue and colleagues
report that a functional polymorphism within G72  (rs
2391191, M15) was associated with poorer verbal mem-
ory performance among patients with schizophrenia [37].
Taken together, these studies show that functional poly-
morphisms in the G72 gene region have an impact on cog-
nitive functions. This impact seems to be most notable in
psychiatric samples. Our study further extends these pre-
vious findings and show that the SNPs in the G72 gene
complex have also an impact on cognitive functions in
healthy controls.
Our results suggest that, at least for markers M23 and
M24, the high-risk genotype of G72 has no negative effect
on cognitive functions in healthy individuals per se, but
even a positive effect in some cognitive domains (such as
verbal working memory and attention). This finding is at
first glance counterintuitive, but might be explained by a
number of reasons. First, the M23-M24 risk haplotype
might influence cognitive functions independent of its
role as a risk factor for psychiatric disorders. A similar
explanation has been proposed by Opgen-Rhine and col-
leagues who also report that a risk haplotype in the G72
region is associated with better performance in semantic
processing both in patients with schizophrenia and con-
trol subjects [36]. Second, from a standpoint of evolution-
ary theory, it might be argued that the risk variant of G72
is maintained in the population since it has a beneficial
influence on cognitive functions which has a positive
effect for evolutionary selection [36]. At last, it cannot be
fully excluded that at least some of the results represent
false positive findings. It is for instance in particular diffi-
cult to understand why the intermediate risk group has a
significant worse performance in the d2-test in compari-
son to both the high- and the low-risk group. A limitation
of our study is that we cannot give a stringent neurobio-
Table 3: Risk status calculated by M24:
G72 risk status (M24) low intermediate high F p
a: Subjects' characteristics
number of subjects 88 220 115
Sex ratio (men/women) 43/45 109/111 62/53 0.709 .702
Age (years) 25.0 (6.7) 24.8 (6.2) 24.1 (4.4) 0.718 .489
Education (years) 15.5 (2.6) 15.5 (2.9) 15.6 (2.2) 0.010 .990
b: Cognitive variables
Spatial span 19.09 (2.88) 18.84 (3.15) 19.50 (2.62) 1.900 .151
Letter-number-span test 16.36 (2.52) 16.23 (2.55) 17.31 (2.28) 7.600 .001
Trail Making Test 58.29 (15.00) 62.84 (19.50) 57.85 (16.34) 3.845 .022
Semantic verbal fluency 30.75 (8.88) 30.86 (9.22) 32.72 (9.56) 1.754 .174
Lexical verbal fluency 17.38 (4.25) 16.47 (4.53) 16.98 (4.90) 1.348 .261
d2-test 201.3 (35.7) 187.7 (33.7) 198.4 (33.4) 6.663 .001BMC Psychiatry 2009, 9:60 http://www.biomedcentral.com/1471-244X/9/60
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logical explanation for these findings. However, all results
are based on a large cohort (n = 423), were obtained by
stringent statistical analyses and survived Bonferroni cor-
rected thresholds, reducing the likelihood of this interpre-
tation.
The functional mechanisms of G72  are still not fully
understood. Chumakov and colleagues showed that the
G72 protein (which is only known in higher primates)
activates a second protein, D-amino acid oxidase
(DAAO), that is involved in the mechanisms of D-serine
[38]. D-serine is an agonist at the glycine modulation site
of the N-methyl-D-aspartate (NMDA) receptor [39]. Thus,
G72 might work as an indirect modulator of NMDA neu-
rotransmission, which has been implicated in various cog-
nitive domains. Lower serum level of D-serine has been
shown, for instance, in patients with schizophrenia. Fur-
thermore, the administration of D-serine (as add-on med-
ication) has been shown to reduce some of the symptoms
in schizophrenia [40]. This provides a potential link
between G72 and the glutamate hypofunction hypothesis
of schizophrenia [41]. Another study however failed to
confirm the interaction between G72  and DAAO [42].
Rather, LG72, a splicing isoform of the G72 gene, encodes
for a mitrochondrial protein. It was shown that an overex-
pression of G72 led to mitrochondrial fragmentation. The
authors proposed that an unknown function of the G72 in
modulating mitochondrial morphology might be respon-
sible for the risk-conferring property of the gene.
Several fMRI studies suggest a modulatory role of G72 on
brain activity in the medial temporal lobe (MTL), in par-
ticular the hippocampus and parahippocampus
[25,35,43]. Goldberg and colleagues showed that healthy
control subjects carrying the homozygous high-risk T/T
allele at SNP M24 had decreased brain activity of the right
hippocampus and left parahippocampus during an epi-
sodic memory encoding task [35]. Hall et al. investigated
subjects with a high familial risk for schizophrenia and
report brain activation differences related to the G72 gen-
otype (as assessed by SNPs M23 and M24) in the left hip-
pocampus and parahippocampus during a verbal
sentence completion task [43]. Jansen and colleagues
showed that in healthy control subjects the G72 genotype
(determined by SNPs M23 and M24) is correlated with
brain activity of the right parahippocampus during a
working memory task [25].
Conclusion
Taken together, these findings can be summarized as fol-
lows:
1. G72 is a vulnerability gene for several psychiatric
disorders, including schizophrenia, bipolar disorder,
major depression, and panic disorder [14]. However,
about 25% of the general population, as suggested by
the present study, carry the high-risk-variant, making a
direct negative effect of the "high-risk" haplotype of
G72 unlikely.
2. The high-risk variant increases the risk for cognitive
impairments in patients with schizophrenia, that is,
when the disorder is already in an acute state [35].
However, the high-risk haplotype does not negatively
affect cognitive abilities per se, but has a beneficial
influence on some cognitive functions in healthy indi-
viduals (as shown in the present study). This might be
one reason, why the allele has not been selected out
during evolution.
3. Functional imaging studies suggest a modulatory
influence of G72 on brain activity in the MTL (hippoc-
ampus, parahippocampus) [25,35,43]. These struc-
tures are involved in the pathogenesis of affective
disorders and particularly schizophrenia [44,45].
The mechanism of G72 might therefore be explained by
the following hypothesis:
G72 has a modulatory influence on brain activity in the
MTL. The high-risk variant has overall a positive effect on
cognitive abilities, but also increases the risk, in combina-
tion with other (unknown) genetic and epigenetic factors,
to increase the risk for psychiatric disorders via its modu-
latory influence on the MTL structures.
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Appendix
In a post-hoc analysis, we additionally analysed all data
separately for group classifications depending solely on
the M23 and M24 status, respectively. The principal
results did not change. This is not surprising, since both
markers are highly correlated (r = 0.94). In this appendix,
we additionally present the results of these analyses. See
tables 2 and 3.
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